Drug
Calaspargase pegol clinical trials
Also written Asparlas and EZN-2285.
- studies test it
- 12
- open now
- 5
- in phase 3
- 4
- first study started
- 1999
Keep track of what changes. Save the calaspargase pegol studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Brand
Development codes
Studies by the year they started
12 studies that test it; most in 2023 (3)
| Year | Studies |
|---|---|
| 1999 | 1 |
| 2008 | 1 |
| 2017 | 1 |
| 2019 | 1 |
| 2021 | 2 |
| 2022 | 1 |
| 2023 | 3 |
| 2025 | 2 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 4
- Phase 2
- 4
- Phase 3
- 4
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 0 · Other 12
Children's Oncology Group (3) · St. Jude Children's Research Hospital (2) · West Virginia University (1) · OHSU Knight Cancer Institute (1) · M.D. Anderson Cancer Center (1) · New York Medical College (1) · Andrew E. Place, MD (1) · H. Lee Moffitt Cancer Center and Research Institute (1)
Often tested with
Tested in the same studies.
Dexamethasone (4) · Pegaspargase (3) · Prednisone (3) · Daunorubicin (3) · Cyclophosphamide (3) · Methotrexate (3) · Cytarabine (2) · Mercaptopurine (2)
Studies
Open first, then newest update. How each study uses calaspargase pegol is read from its arms, and is right about nine times in ten.
Testing it · 12
- A Phase 2 Study to Evaluate Efficacy of Calaspargase Pegol-mknl and Decitabine Combined With Venetoclax in Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and T- Cell Lymphoblastic Lymphoma (T-LLy)RecruitingPhase 2M.D. Anderson Cancer CenterNCT06561074Written as Calaspargase pegol-mknl
- Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/LymphomaRecruitingEarly Phase 1New York Medical CollegeNCT03719105Written as calaspargase pegol
- Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and LymphomaRecruitingPhase 2St. Jude Children's Research HospitalNCT06533748Written as Calaspargase
- Venetoclax Basket Trial for High Risk Hematologic MalignanciesRecruitingPhase 1Andrew E. Place, MDNCT05292664Written as Calaspargase Pegol
- CalPeg for Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)RecruitingPhase 1H. Lee Moffitt Cancer Center and Research InstituteNCT05581030Written as Calaspargase Pegol
- Phase 1 of Calaspargase Pegol-mknl W/ Cytarabine and Idarubicin in Newly Diagnosed AMLActive, not recruitingPhase 1West Virginia UniversityNCT04953780Written as Calaspargase pegol-mknl
- Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or LymphomaActive, not recruitingPhase 3Children's Oncology GroupNCT05602194Written as Calaspargase Pegol
- Calaspargase Pegol-Mnkl and Cobimetinib for the Treatment of Locally Advanced or Metastatic Pancreatic CancerCompletedPhase 1OHSU Knight Cancer InstituteNCT05034627Written as Calaspargase Pegol-mknl
- Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and LymphomaActive, not recruitingPhase 2/3St. Jude Children's Research HospitalNCT03117751Written as Calaspargase Pegol
- SPARK-ALL: Calaspargase Pegol in Adults With ALLTerminatedPhase 2/3Institut de Recherches Internationales ServierNCT04817761Written as Calaspargase pegol (S95015)
- Calaspargase Pegol or Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic LeukemiaCompletedPhase 3Children's Oncology GroupNCT00671034Written as Calaspargase Pegol-mknl
- Biomarkers to Classify Young Patients With Acute Lymphoblastic Leukemia (ALL) and Remission Induction Therapy in Young Patients With B-Precursor ALLCompletedNot applicableChildren's Oncology GroupNCT01225874Written as SC-PEG E. coli L-asparaginase
Given in every arm · 12 — calaspargase pegol is usual care beside what is tested
- A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)RecruitingPhase 2National Cancer Institute (NCI)NCT06124157Written as Calaspargase Pegol
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged LeukemiaRecruitingPhase 2National Cancer Institute (NCI)NCT06317662Written as Calaspargase Pegol
- Testing Blinatumomab With or Without Revumenib in Patients With B-cell Acute Lymphoblastic Leukemia With a Genetic Change Requiring More TreatmentNot yet recruitingPhase 2SWOG Cancer Research NetworkNCT07636564Written as Calaspargase Pegol
- A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)RecruitingPhase 2National Cancer Institute (NCI)NCT04546399Written as Calaspargase Pegol
- Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLyRecruitingPhase 3Children's Oncology GroupNCT03959085Written as Calaspargase Pegol
- Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)RecruitingPhase 2St. Jude Children's Research HospitalNCT06390319Written as Calaspargase pegol
- Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)Not yet recruitingPhase 2/3Children's Oncology GroupNCT07072585Written as Calaspargase Pegol
- Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and NavitoclaxActive, not recruitingPhase 1/2St. Jude Children's Research HospitalNCT05192889Written as Calaspargase Pegol
- Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic LeukemiaActive, not recruitingPhase 3Children's Oncology GroupNCT03007147Written as Calaspargase Pegol
- Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic LeukemiaActive, not recruitingPhase 2Children's Oncology GroupNCT02981628Written as Calaspargase Pegol
- A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory LeukemiaActive, not recruitingPhase 2Children's Oncology GroupNCT05761171Written as Calaspargase Pegol
- Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL)WithdrawnPhase 2National Cancer Institute (NCI)NCT06210750Written as Calaspargase Pegol
Codes
What other systems call calaspargase pegol · ClinicalTrials.gg INT000169
- MeSH (NLM) C000595188calaspargase pegolOne source ClinicalTrials.gov
- UNII (FDA) T9FVH03HMZCALASPARGASE PEGOLConfirmed FDA, Wikidata
- RxNorm 2121416One source FDA
- Wikidata Q60676224calaspargase pegol-mknlConfirmed FDA, Wikidata
- NCI Thesaurus C78198Calaspargase PegolOne source FDA
- DrugBank DB14730One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000595188 | calaspargase pegol | One source ClinicalTrials.gov |
| UNII (FDA) | T9FVH03HMZ | CALASPARGASE PEGOL | Confirmed FDA, Wikidata |
| RxNorm | 2121416 | — | One source FDA |
| Wikidata | Q60676224 | calaspargase pegol-mknl | Confirmed FDA, Wikidata |
| NCI Thesaurus | C78198 | Calaspargase Pegol | One source FDA |
| DrugBank | DB14730 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.